Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Western Alliance Bancorporation — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Western Alliance Bancorporation trades at $72.03 (market cap $8.04B). The key difference: Western Alliance Bancorporation is far larger — about 8.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Western Alliance Bancorporation pays a 2.28% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Western Alliance Bancorporation for 3 Days on average.
| MRVI | WAL | |
|---|---|---|
Market Cap | $972.90M | $8.04B |
Volume | 4,325,710 | 1,433,355 |
Sector | Health | Financials |
52-Week High | $9.00 | $96.08 |
52-Week Low | $2.83 | $66.70 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $1.08B | $9.57B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Western Alliance Bancorporation (WAL) trades at $73.73, down 1.29% on the day, reflecting a bearish technical signal despite strong fundamentals. The stock shows solid profitability with a 25.43% net income margin and attractive valuation ratios, including a P/E of 8.32. Recent earnings have mostly beaten estimates, and the company launched WA VenueX, a new financial platform. Analyst consensus is strongly bullish with a $85.09 price target, though technical indicators point to near-term weakness.
The outlook for WAL is positive based on fundamentals and analyst support, but technical headwinds and interest rate sensitivity pose risks. Upside potential exists if the stock rebounds from support levels and executes on growth initiatives, while downside could stem from macroeconomic pressures or missed earnings. The high institutional ownership and recent dividend announcement signal confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
